Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,876,896 papers from all fields of science
Search
Sign In
Create Free Account
P 7521
Known as:
P-7521
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Bridged Bicyclo Compounds, Heterocyclic
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
A potent and long-lasting ligand, azabicyclononane (P-7521).
Chi Zq
,
Jin Wq
1990
Corpus ID: 88761347
1990
1990
A potent and long-lasting ligand, azabicyclononane (P-7521).
Z. Chi
,
W. Jin
Progress in clinical and biological research
1990
Corpus ID: 30778384
1989
1989
P-7521--a new irreversible opioid ligand.
W. Jin
,
L. Fan
,
X. Chen
,
Z. Chi
Zhongguo yao li xue bao = Acta pharmacologica…
1989
Corpus ID: 1868767
In the receptor binding assay, P-7521 was a potent opioid ligand which acted mainly on mu receptor. The relative affinity ratio…
Expand
1988
1988
[Effects of the long-acting analgesics 3-(beta-phenylethyl)-9 beta-methoxy-9 alpha-(m-hydroxyphenyl)-3-azabicycles [3,3,1]-nonane (P-7521) on opiate receptor binding in vitro].
D. Zhou
,
B. Ge
,
X. J. Xu
,
Z. Chi
Zhongguo yao li xue bao = Acta pharmacologica…
1988
Corpus ID: 21986692
After 6 washes, rat brain P2 membranes preincubated with P-7521 showed only a 15% recovery of [3H]etorphine binding activity…
Expand
1987
1987
[Analgesic activity and respiratory inhibition of 3-beta-phenylethyl)-9 beta-methoxy-9 alpha-(m-hydroxyphenyl)-3-azabicyclo [3,3,1]-nonane (P-7521) in rabbits].
J. Zhou
,
W. Zheng
,
Z. Chi
Zhongguo yao li xue bao = Acta pharmacologica…
1987
Corpus ID: 28008266
P-7521 is an azabicycloalkane derivative. When P-7521 was given iv to rabbits, its analgesic ED50 was 0.37μg/kg, the analgesic…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE